Streamlining the Route of Administration of Monoclonal Antibody Therapies for Better Patient Outcomes in the NSCLC Population

Subcutaneous vs IV Amivantamab

• PALOMA-3 study findings:
• Similar efficacy: 30% response rate (subcutaneous) vs 33% (IV)

• Improved PFS: 6.1 months (subcutaneous) vs 4.3 months (IV) in heavily pretreated population

• Significantly reduced IRRs: 13% (subcutaneous) vs 66% (IV)

• Fewer venous thromboembolism events with subcutaneous administration
• Operational advantages:
• Dramatically reduced administration time: 5 minutes (subcutaneous) vs 5 hours (IV)

• Improved infusion chair turnover

• No split dosing required (unlike IV which requires day 1/day 2 split)

• Patient preference: 85% rated subcutaneous as convenient vs 35% for IV

• Not yet FDA approved outside clinical trials